{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:42:07Z","timestamp":1788914527847,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["FOR 2722"],"award-info":[{"award-number":["FOR 2722"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40272-019-00330-0","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T03:13:17Z","timestamp":1554347597000},"page":"95-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Current and Emerging Therapeutic Options for the Management of Rare Skeletal Diseases"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-7556","authenticated-orcid":false,"given":"Oliver","family":"Semler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Rehberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nava","family":"Mehdiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Jackels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Hoyer-Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"330_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13023-016-0398-y","volume":"11","author":"T Evangelista","year":"2016","unstructured":"Evangelista T, et al. The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis. 2016;11:17.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"330_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-017-0676-3","volume":"12","author":"V Heon-Klin","year":"2017","unstructured":"Heon-Klin V. European Reference networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. 2017;12(1):137.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"330_CR3","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/ajmg.a.36668","volume":"164A","author":"S Nampoothiri","year":"2014","unstructured":"Nampoothiri S, et al. Eight years experience from a skeletal dysplasia referral center in a tertiary hospital in Southern India: a model for the diagnosis and treatment of rare diseases in a developing country. Am J Med Genet A. 2014;164A(9):2317\u201323.","journal-title":"Am J Med Genet A"},{"key":"330_CR4","doi-asserted-by":"publisher","first-page":"540178","DOI":"10.4061\/2011\/540178","volume":"2011","author":"IM Ben Amor","year":"2011","unstructured":"Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;2011:540178.","journal-title":"J Osteoporos."},{"issue":"6","key":"330_CR5","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/ajmg.a.35938","volume":"161A","author":"JA Caparros-Martin","year":"2013","unstructured":"Caparros-Martin JA, et al. Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotype-phenotype correlations. Am J Med Genet A. 2013;161A(6):1354\u201369.","journal-title":"Am J Med Genet A"},{"issue":"10","key":"330_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ejhg.2014.10","volume":"22","author":"C Hofmann","year":"2014","unstructured":"Hofmann C, et al. Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet. 2014;22(10):1160\u20134.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"330_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.14740\/jocmr2465w","volume":"8","author":"A Al Kaissi","year":"2016","unstructured":"Al Kaissi A, et al. The Diversity of the clinical phenotypes in patients with fibrodysplasia ossificans progressiva. J Clin Med Res. 2016;8(3):246\u201353.","journal-title":"J Clin Med Res"},{"issue":"5","key":"330_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/pd.2729","volume":"31","author":"P Yeh","year":"2011","unstructured":"Yeh P, et al. Accuracy of prenatal diagnosis and prediction of lethality for fetal skeletal dysplasias. Prenat Diagn. 2011;31(5):515\u20138.","journal-title":"Prenat Diagn"},{"issue":"1","key":"330_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00404-016-4090-1","volume":"294","author":"M Cozzolino","year":"2016","unstructured":"Cozzolino M, et al. Ultrasonographic early diagnosis of osteogenesis imperfecta type I: implications for pre and post-natal therapy. Arch Gynecol Obstet. 2016;294(1):215\u20136.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"330_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/gim.2015.131","volume":"18","author":"S Bellur","year":"2016","unstructured":"Bellur S, et al. Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta. Genet Med. 2016;18(6):570\u20136.","journal-title":"Genet Med"},{"issue":"6","key":"330_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ajog.2018.07.017","volume":"219","author":"R Savarirayan","year":"2018","unstructured":"Savarirayan R, et al. Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia. Am J Obstet Gynecol. 2018;219(6):545\u201362.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"330_CR12","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/ajmg.a.37365","volume":"167A","author":"L Bonafe","year":"2015","unstructured":"Bonafe L, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869\u201392.","journal-title":"Am J Med Genet A"},{"issue":"13\u201314","key":"330_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10354-015-0368-3","volume":"165","author":"N Fratzl-Zelman","year":"2015","unstructured":"Fratzl-Zelman N, et al. Classification of osteogenesis imperfecta. Wien Med Wochenschr. 2015;165(13\u201314):264\u201370.","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"330_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","volume":"88","author":"J Becker","year":"2011","unstructured":"Becker J, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011;88(3):362\u201371.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"330_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00112-017-0321-1","volume":"165","author":"H Hoyer-Kuhn","year":"2017","unstructured":"Hoyer-Kuhn H, Rehberg M, Semler O. Angeborene Skeletterkrankungen. Monatsschrift Kinderheilkunde. 2017;165(8):663\u201371.","journal-title":"Monatsschrift Kinderheilkunde"},{"issue":"5","key":"330_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000313380","volume":"74","author":"R Beccard","year":"2010","unstructured":"Beccard R, et al. Do bone mineral density, bone geometry and the functional muscle-bone unit explain bone fractures in healthy children and adolescents? Horm Res Paediatr. 2010;74(5):312\u20138.","journal-title":"Horm Res Paediatr"},{"issue":"Suppl 1","key":"330_CR17","first-page":"63","volume":"45","author":"E Schonau","year":"1996","unstructured":"Schonau E, et al. Influence of muscle strength on bone strength during childhood and adolescence. Horm Res. 1996;45(Suppl 1):63\u20136.","journal-title":"Horm Res"},{"issue":"6","key":"330_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bone.2004.11.014","volume":"36","author":"J Rittweger","year":"2005","unstructured":"Rittweger J, et al. Muscle atrophy and bone loss after 90\u00a0days\u2019 bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study. Bone. 2005;36(6):1019\u201329.","journal-title":"Bone"},{"issue":"5","key":"330_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137.","journal-title":"Nat Genet"},{"key":"330_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fcell.2015.00051","volume":"3","author":"SV Komarova","year":"2015","unstructured":"Komarova SV, et al. Mathematical model for bone mineralization. Front Cell Dev Biol. 2015;3:51.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"330_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s11914-014-0218-z","volume":"12","author":"P Roschger","year":"2014","unstructured":"Roschger P, et al. Changes in the degree of mineralization with osteoporosis and its treatment. Curr Osteoporos Rep. 2014;12(3):338\u201350.","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"330_CR22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jbmr.3662","volume":"34","author":"JB Meurs van","year":"2019","unstructured":"van Meurs JB, et al. Role of epigenomics in bone and cartilage disease. J Bone Miner Res. 2019;34(2):215\u201330.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"330_CR23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/jbmr.3148","volume":"32","author":"JA Morris","year":"2017","unstructured":"Morris JA, et al. Epigenome-wide association of DNA methylation in whole blood with bone mineral density. J Bone Miner Res. 2017;32(8):1644\u201350.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"330_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jbmr.3298","volume":"33","author":"E Fernandez-Rebollo","year":"2018","unstructured":"Fernandez-Rebollo E, et al. Primary osteoporosis is not reflected by disease-specific DNA methylation or accelerated epigenetic age in blood. J Bone Miner Res. 2018;33(2):356\u201361.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"330_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11914-018-0434-z","volume":"16","author":"LM Ward","year":"2018","unstructured":"Ward LM, Rauch F. Anabolic therapy for the treatment of osteoporosis in childhood. Curr Osteoporos Rep. 2018;16(3):269\u201376.","journal-title":"Curr Osteoporos Rep"},{"issue":"10028","key":"330_CR26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657\u201371.","journal-title":"Lancet"},{"key":"330_CR27","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"330_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-018-0905-4","volume":"13","author":"B Mueller","year":"2018","unstructured":"Mueller B, et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet J Rare Dis. 2018;13(1):158.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"330_CR29","first-page":"445","volume":"14","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, et al. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact. 2014;14(4):445\u201353.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"8","key":"330_CR30","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1210\/jc.2017-00275","volume":"102","author":"W Hogler","year":"2017","unstructured":"Hogler W, et al. The effect of whole body vibration training on bone and muscle function in children with osteogenesis imperfecta. J Clin Endocrinol Metab. 2017;102(8):2734\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"330_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11832-011-0341-7","volume":"5","author":"J Ruck","year":"2011","unstructured":"Ruck J, et al. Fassier\u2013Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop. 2011;5(3):217\u201324.","journal-title":"J Child Orthop"},{"issue":"1","key":"330_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BPO.0000000000000729","volume":"38","author":"E Ashby","year":"2018","unstructured":"Ashby E, et al. Functional outcome of humeral rodding in children with osteogenesis imperfecta. J Pediatr Orthop. 2018;38(1):49\u201353.","journal-title":"J Pediatr Orthop"},{"issue":"9","key":"330_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00132-012-1959-y","volume":"41","author":"T Wirth","year":"2012","unstructured":"Wirth T. Osteogenesis imperfecta. Orthopade. 2012;41(9):773\u201382 (quiz 83\u20134).","journal-title":"Orthopade"},{"issue":"4","key":"330_CR34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/BPB.0000000000000405","volume":"27","author":"JM Franzone","year":"2018","unstructured":"Franzone JM, Kruse RW. Intramedullary nailing with supplemental plate and screw fixation of long bones of patients with osteogenesis imperfecta: operative technique and preliminary results. J Pediatr Orthop B. 2018;27(4):344\u20139.","journal-title":"J Pediatr Orthop B"},{"issue":"1","key":"330_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","volume":"87","author":"E Astrom","year":"1998","unstructured":"Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr. 1998;87(1):64\u20138.","journal-title":"Acta Paediatr"},{"issue":"14","key":"330_CR36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947\u201352.","journal-title":"N Engl J Med"},{"issue":"5","key":"330_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005;20(5):758\u201363.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"330_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","volume":"149","author":"F Antoniazzi","year":"2006","unstructured":"Antoniazzi F, et al. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr. 2006;149(2):174\u20139.","journal-title":"J Pediatr"},{"issue":"1","key":"330_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18(1):126\u201330.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"330_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000331128","volume":"76","author":"O Semler","year":"2011","unstructured":"Semler O, et al. Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. Horm Res Paediatr. 2011;76(5):321\u20137.","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"330_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00774-009-0149-4","volume":"28","author":"I Panigrahi","year":"2010","unstructured":"Panigrahi I, et al. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab. 2010;28(4):451\u20135.","journal-title":"J Bone Miner Metab"},{"issue":"8","key":"330_CR42","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1515\/jpem-2015-0351","volume":"29","author":"C Kumar","year":"2016","unstructured":"Kumar C, et al. Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children. J Pediatr Endocrinol Metab. 2016;29(8):947\u201352.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"330_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/archdischild-2017-313234","volume":"103","author":"V Saraff","year":"2018","unstructured":"Saraff V, et al. Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis. Arch Dis Child. 2018;103(1):92\u20134.","journal-title":"Arch Dis Child"},{"key":"330_CR44","first-page":"CD005088","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan K, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"330_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17(1):30\u20138.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"330_CR46","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, et al. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007;40(3):638\u201344.","journal-title":"Bone"},{"issue":"3","key":"330_CR47","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183\u20138.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"330_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, et al. Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9(1):145.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"330_CR49","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24\u201332.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"8","key":"330_CR50","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1210\/jc.2013-1143","volume":"98","author":"C Grasemann","year":"2013","unstructured":"Grasemann C, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget\u2019s disease. J Clin Endocrinol Metab. 2013;98(8):3121\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"330_CR51","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward L. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2018;18(1):76\u201380.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"3","key":"330_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5414\/CP203361","volume":"57","author":"F Bandeira","year":"2019","unstructured":"Bandeira F, et al. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate. Int J Clin Pharmacol Ther. 2019;57(3):163\u20136.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"2","key":"330_CR53","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190\u20138.","journal-title":"J Bone Miner Res"},{"key":"330_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.02.007","author":"H Florez","year":"2019","unstructured":"Florez H, et al. Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature. Semin Arthritis Rheum. 2019. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.007 .","journal-title":"Semin Arthritis Rheum."},{"key":"330_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bone.2016.09.013","volume":"93","author":"JE Perosky","year":"2016","unstructured":"Perosky JE, et al. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+\u2009osteogenesis imperfecta model. Bone. 2016;93:79\u201385.","journal-title":"Bone"},{"issue":"1","key":"330_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.2154","volume":"29","author":"BO Williams","year":"2014","unstructured":"Williams BO. Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J Bone Miner Res. 2014;29(1):24\u20138.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"330_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1759720X17726744","volume":"9","author":"MR McClung","year":"2017","unstructured":"McClung MR. Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Ther Adv Musculoskelet Dis. 2017;9(10):263\u201370.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"330_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder BP, et al. Sclerostin antibody improves skeletal parameters in a Brtl\/+\u2009mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73\u201380.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"330_CR59","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux FH, et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res. 2017;32(7):1496\u2013504.","journal-title":"J Bone Miner Res"},{"issue":"13","key":"330_CR60","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"99","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99(13):8932\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"330_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","volume":"5","author":"EM Horwitz","year":"1999","unstructured":"Horwitz EM, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5(3):309\u201313.","journal-title":"Nat Med"},{"issue":"11","key":"330_CR62","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","volume":"79","author":"K Blanc Le","year":"2005","unstructured":"Le Blanc K, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79(11):1607\u201314.","journal-title":"Transplantation"},{"key":"330_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fphar.2014.00223","volume":"5","author":"JK Chan","year":"2014","unstructured":"Chan JK, Gotherstrom C. Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Front Pharmacol. 2014;5:223.","journal-title":"Front Pharmacol"},{"issue":"2","key":"330_CR64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5966\/sctm.2013-0090","volume":"3","author":"C Gotherstrom","year":"2014","unstructured":"Gotherstrom C, et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med. 2014;3(2):255\u201364.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"330_CR65","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/pd.4611","volume":"35","author":"M Westgren","year":"2015","unstructured":"Westgren M, Gotherstrom C. Stem cell transplantation before birth\u2014a realistic option for treatment of osteogenesis imperfecta? Prenat Diagn. 2015;35(9):827\u201332.","journal-title":"Prenat Diagn"},{"issue":"Suppl 1","key":"330_CR66","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/uog.17084","volume":"48","author":"LS Chitty","year":"2016","unstructured":"Chitty LS, et al. EP21.04: BOOSTB4: a clinical study to determine safety and efficacy of pre- and\/or postnatal stem cell transplantation for treatment of osteogenesis imperfecta. Ultrasound Obstet Gynecol. 2016;48(Suppl 1):356.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"330_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14(1):1.","journal-title":"Orphanet J Rare Dis"},{"key":"330_CR68","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.6061\/clinics\/2018\/e324","volume":"73","author":"JRM Ceroni","year":"2018","unstructured":"Ceroni JRM, et al. Natural history of 39 patients with achondroplasia. Clinics (Sao Paulo). 2018;73:e324.","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"330_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12519-016-0051-9","volume":"13","author":"M Zaffanello","year":"2017","unstructured":"Zaffanello M, et al. Sleep disordered breathing in children with achondroplasia. World J Pediatr. 2017;13(1):8\u201314.","journal-title":"World J Pediatr"},{"issue":"6","key":"330_CR70","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3349\/ymj.2015.56.6.1656","volume":"56","author":"KW Park","year":"2015","unstructured":"Park KW, et al. Limb lengthening in patients with achondroplasia. Yonsei Med J. 2015;56(6):1656\u201362.","journal-title":"Yonsei Med J"},{"issue":"3","key":"330_CR71","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3171\/2018.9.PEDS18410","volume":"23","author":"JL Nadel","year":"2018","unstructured":"Nadel JL, et al. Screening and surgery for foramen magnum stenosis in children with achondroplasia: a large, national database analysis. J Neurosurg Pediatr. 2018;23(3):374\u201380.","journal-title":"J Neurosurg Pediatr."},{"issue":"1","key":"330_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000446958","volume":"86","author":"M Miccoli","year":"2016","unstructured":"Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm Res Paediatr. 2016;86(1):27\u201334.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"330_CR73","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","volume":"91","author":"F Lorget","year":"2012","unstructured":"Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91(6):1108\u201314.","journal-title":"Am J Hum Genet"},{"key":"330_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mrrev.2013.11.001","volume":"759","author":"P Krejci","year":"2014","unstructured":"Krejci P. The paradox of FGFR3 signaling in skeletal dysplasia: why chondrocytes growth arrest while other cells over proliferate. Mutat Res Rev Mutat Res. 2014;759:40\u20138.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"330_CR75","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000439334","volume":"30","author":"L Legeai-Mallet","year":"2016","unstructured":"Legeai-Mallet L. C-type natriuretic peptide analog as therapy for achondroplasia. Endocr Dev. 2016;30:98\u2013105.","journal-title":"Endocr Dev"},{"issue":"13","key":"330_CR76","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1177\/0022034517716437","volume":"96","author":"S Yamanaka","year":"2017","unstructured":"Yamanaka S, et al. Circulatory CNP rescues craniofacial hypoplasia in achondroplasia. J Dent Res. 2017;96(13):1526\u201334.","journal-title":"J Dent Res"},{"issue":"203","key":"330_CR77","doi-asserted-by":"publisher","first-page":"203ra124","DOI":"10.1126\/scitranslmed.3006247","volume":"5","author":"S Garcia","year":"2013","unstructured":"Garcia S, et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci Transl Med. 2013;5(203):203ra124.","journal-title":"Sci Transl Med"},{"issue":"2","key":"330_CR78","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00590-014-1496-y","volume":"25","author":"V Pavone","year":"2015","unstructured":"Pavone V, et al. Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol. 2015;25(2):221\u20136.","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"4","key":"330_CR79","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Investig. 2004;113(4):561\u20138.","journal-title":"J Clin Investig"},{"issue":"26","key":"330_CR80","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, et al. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med. 1991;325(26):1843\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"330_CR81","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O Makitie","year":"2003","unstructured":"Makitie O, et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"330_CR82","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig. 2014;124(4):1587\u201397.","journal-title":"J Clin Investig"},{"issue":"21","key":"330_CR83","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"330_CR84","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, et al. Efficacy and safety of burosumab in children aged 1\u20134\u00a0years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"330_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP. Hypophosphatasia\u2014aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12(4):233\u201346.","journal-title":"Nat Rev Endocrinol"},{"key":"330_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2013.177","author":"E Mornet","year":"2014","unstructured":"Mornet E, et al. Clinical utility gene card for: hypophosphatasia\u2014update 2013. Eur J Hum Genet. 2014. https:\/\/doi.org\/10.1038\/ejhg.2013.177 .","journal-title":"Eur J Hum Genet."},{"key":"330_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: an overview for 2017. Bone. 2017;102:15\u201325.","journal-title":"Bone"},{"key":"330_CR88","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bone.2016.08.019","volume":"93","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Wenkert D, Zhang F. Hypophosphatasia: natural history study of 101 affected children investigated at one research center. Bone. 2016;93:125\u201338.","journal-title":"Bone"},{"issue":"1","key":"330_CR89","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1515\/cclm-2016-0318","volume":"55","author":"J Zierk","year":"2017","unstructured":"Zierk J, et al. Pediatric reference intervals for alkaline phosphatase. Clin Chem Lab Med. 2017;55(1):102\u201310.","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"330_CR90","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"330_CR91","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/jc.2015-3462","volume":"101","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"330_CR92","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cen.13343","volume":"87","author":"T Kitaoka","year":"2017","unstructured":"Kitaoka T, et al. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial. Clin Endocrinol (Oxf). 2017;87(1):10\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"330_CR93","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02335","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, et al. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019. https:\/\/doi.org\/10.1210\/jc.2018-02335 .","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"330_CR94","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrrheum.2010.122","volume":"6","author":"EM Shore","year":"2010","unstructured":"Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol. 2010;6(9):518\u201327.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"330_CR95","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","volume":"22","author":"FS Kaplan","year":"2008","unstructured":"Kaplan FS, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191\u2013205.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"330_CR96","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011;17(4):454\u201360.","journal-title":"Nat Med"},{"key":"330_CR97","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13823","author":"KL Wentworth","year":"2018","unstructured":"Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2018. https:\/\/doi.org\/10.1111\/bcp.13823 .","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"330_CR98","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1566524016666151222142446","volume":"16","author":"Y Luo","year":"2016","unstructured":"Luo Y, et al. Development of new therapeutic agents for fibrodysplasia ossificans progressiva. Curr Mol Med. 2016;16(1):4\u201311.","journal-title":"Curr Mol Med"},{"issue":"Suppl 1","key":"330_CR99","first-page":"MON-1066","volume":"33","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, et al. Palovarotene reduces new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP). JBMR. 2018;33(Suppl 1):MON-1066.","journal-title":"JBMR"},{"issue":"4","key":"330_CR100","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jbmr.3341","volume":"33","author":"T Inubushi","year":"2018","unstructured":"Inubushi T, et al. Palovarotene inhibits osteochondroma formation in a mouse model of multiple hereditary exostoses. J Bone Miner Res. 2018;33(4):658\u201366.","journal-title":"J Bone Miner Res"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00330-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:37:57Z","timestamp":1694774277000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00330-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00330-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"3 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Parts of this work were supported by \u201cDeutsche Forschungsgemeinschaft\u201d through Grant FOR 2722 to authors OS and MR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HHK, MR and OS have received speaker\u2019s fees and travel Grants from different companies in the past. HHK and OS have received research Grants from Amgen and Alexion. NM and MJ have not received any support from companies producing drugs mentioned in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}